Danaher(US:DHR) Jing Ji Guan Cha Wang·2026-02-11 17:04Company Performance - The company plans to release its Q4 and full-year 2025 financial results in late February 2026, with management indicating that performance will exceed expectations [2] - The core revenue growth target for fiscal year 2026 is set at 3% to 6%, with an adjusted operating margin expected to expand by over 100 basis points and adjusted EPS targeted for high single-digit growth [3] Industry Conditions - Growth in 2026 is expected to be driven by the continued recovery in the life sciences market, increased demand for bioprocessing equipment, and a rebound in the Chinese diagnostics market [4] Strategic Initiatives - The company notes that the merger and acquisition environment is improving and emphasizes a disciplined approach focused on strategic targets within its biotechnology, life sciences, and diagnostics core sectors [5]